Final fall, Obagi Medical formally entered the injectable house with the launch of Saypha MagIQ, its FDA-approved hyaluronic acid filler for reasonable to extreme nasolabial folds. The transfer marked a serious evolution for the skin-care big, placing it in direct competitors with established filler portfolios like RHA, Restylane and Juvéderm.
This week, the model expanded that portfolio once more. Obagi introduced FDA approval of Saypha ChIQ, a hyaluronic acid filler designed for cheek augmentation and correction of midface contour deficiencies in sufferers over 21. The brand new approval makes ChIQ the second injectable below Obagi’s rising aesthetics umbrella, additional signaling the model’s ambitions to turn out to be a extra complete participant within the class.
Like MagIQ, ChIQ comes out of Obagi’s partnership with Austria-based Croma-Pharma, the worldwide aesthetics firm behind the Saypha filler line. Whereas the model could really feel newer to U.S. injectors, Croma has been within the injectable house for many years, with greater than 130 million syringes distributed throughout 80 international locations.
On the core of ChIQ is Croma’s MACRO Core Expertise, a specialised hyaluronic acid matrix designed for better elevate and structural help. The result’s a filler higher suited to creating form, contour and projection within the cheeks and midface.
“The FDA approval of ChIQ is thrilling as a result of it fills an essential hole,” says Austin, TX oculoplastic surgeon Sheila Barbarino, MD. “It’s a better G-prime hyaluronic acid filler designed to supply enhanced structural help and elevate. I’ve had nice success with Obagi’s present HA filler, MagIQ, which has turn out to be a real workhorse in my apply due to its versatility, predictability and natural-looking outcomes. The addition of ChIQ expands the portfolio and provides suppliers and sufferers one other beneficial choice for these looking for better definition, contour and longevity whereas sustaining a refined, pure aesthetic.”
With ChIQ, Obagi continues to develop past skincare, constructing out an injectable lineup that enhances the remedies many suppliers are already pairing with topical regimens. And in a crowded filler market, it provides injectors another choice backed by a long time of worldwide expertise.
